carglumic acid

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Ucedane. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ucedane.

For practical information about using Ucedane, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 10/10/2019

Authorisation details

Product details
Agency product number
Active substance
carglumic acid
International non-proprietary name (INN) or common name
carglumic acid
Therapeutic area (MeSH)
  • Hyperammonemia
  • Amino Acid Metabolism, Inborn Errors
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Eurocept International BV
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Trapgans 5
1244 RL Ankeveen
The Netherlands

Product information

30/08/2019 Ucedane - EMEA/H/C/004019 - N/0005


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Other alimentary tract and metabolism products

Therapeutic indication

Treatment of hyperammonaemia due to N-acetylglutamate synthase primary deficiency

Assessment history

How useful was this page?

Add your rating